F-10: Cardiol Therapeutics Files for US$150 Million Shelf Prospectus, Enabling Future Securities Offerings

Cardiol Therapeutics has filed a preliminary short form base shelf prospectus to offer up to US$150 million in common shares, debt securities, warrants, subscription receipts, or units over a 25-month period.

Summary

• Cardiol Therapeutics has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Canada and a corresponding registration statement with the U.S.
• The company may offer and sell up to US$150 million in securities, including Class A common shares, debt securities, warrants, subscription receipts, or units, over a 25-month period.
• The securities may be offered separately or together, in separate series, and the terms will be determined based on market conditions at the time of sale.
• Cardiol intends to use the net proceeds from the sale of securities to advance its business objectives and for general corporate purposes.
• The company's common shares are listed on the TSX under the symbol CRDL and on the Nasdaq Capital Market under the symbol CRDL.
• On July 4, 2024, the closing price of the common shares on the TSX was $2.70, and on the Nasdaq was US$1.92.

Sentiment

Score: 6

Explanation: The announcement is neutral to slightly positive. It provides financial flexibility but also indicates a potential need for capital, which could be viewed as a risk.

Positives

• The shelf prospectus provides Cardiol Therapeutics with financial flexibility to raise capital in the future.
• The company has a range of securities it can offer, allowing it to tailor offerings to market conditions.
• The company has the option to use the proceeds for a variety of purposes, including funding operations, repaying debt, and acquisitions.
• The company has existing listings on both the TSX and Nasdaq, providing access to a broader investor base.

Negatives

• The company had negative operating cash flow in recent years and may need to use proceeds to fund such negative cash flow.
• The company's management will have discretion in the actual application of the proceeds and may elect to allocate proceeds differently from that described under the heading Use of Proceeds if it believes that it would be in the best interests of the Corporation to do so if circumstances change.
• The company may issue additional Common Shares in future offerings (including through the sale of securities convertible into or exchangeable for Common Shares) and on the exercise of stock options or other securities exercisable for Common Shares.

Risks

• The market price of common shares may be adversely affected by a variety of factors relating to the Corporation's business, including fluctuations in the Corporation's operating and financial results, the results of any public announcements made by the Corporation and its failure to meet analysts expectations.
• The market value of Common Shares may also be affected by the Corporations financial results and political, economic, financial, and other factors that can affect the capital markets generally, the stock exchanges on which Common Shares are traded and the market segments in which the Corporation is a part.
• Issuances of a substantial number of additional Common Shares, or the perception that such issuances could occur, may adversely affect prevailing market prices for Common Shares.
• With any additional issuance of Common Shares, investors will suffer dilution to their voting power and may experience dilution in its earnings per share.
• The Corporation may be classified as a passive foreign investment company for U.S. federal income tax purposes, which would subject U.S. investors that hold the Corporations Common Shares to potentially significant adverse U.S. federal income tax consequences.

Future Outlook

The company may offer and sell securities from time to time over the next 25 months, depending on market conditions and its funding needs.

Industry Context

Biopharmaceutical companies often use shelf prospectuses to provide flexibility in accessing capital markets to fund research and development, clinical trials, and commercialization efforts.

Comparison to Industry Standards

• Comparable companies such as Amarin Corporation and Madrigal Pharmaceuticals have utilized shelf offerings to raise capital for similar purposes.
• The size of the offering (US$150 million) is within the typical range for companies at a similar stage of development in the biopharmaceutical industry.
• The specific terms of any future offerings will be determined by market conditions, which is a standard practice.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional common shares.
• Employees may benefit from increased job security and opportunities if the company successfully raises capital and expands its operations.
• Customers may benefit from the development of new therapies if the company uses the proceeds to fund research and development.
• Creditors may be impacted if the company uses the proceeds to repay debt, potentially improving its financial stability.

Next Steps

• Cardiol Therapeutics may file prospectus supplements in the future to detail specific offerings under the shelf prospectus.
• The company will determine the timing and terms of any offerings based on market conditions and its funding needs.

Key Dates

Keywords

shelf prospectus, securities, common shares, debt securities, warrants, subscription receipts, units, Cardiol Therapeutics, offering, capital raise